XML 88 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)
Total
Conversion of principal amount
Conversion of accrued interest
Common Stock 0.001 Par Value
Common Stock 0.001 Par Value
Conversion of principal amount
Common Stock 0.001 Par Value
Conversion of accrued interest
Additional Paid-in Capital
Additional Paid-in Capital
Conversion of principal amount
Additional Paid-in Capital
Conversion of accrued interest
Common Stock Subscription
Shareholder Receivable
Accumulated Deficit
Noncontrolling Interest
Balance, beginning balance at Dec. 31, 2009 $ 2,299,930     $ 46,516     $ 10,058,287         $ (8,192,957) $ 388,084
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Sale of common stock, net of costs 1,211,249     1,863     1,209,386            
Issuance of restricted stock 49,895     77     49,871     (53)      
Note receivable from shareholder (345,000)                   (345,000)    
Exercise of warrants 142,500     475     142,025            
Stock based compensation expense 197,086           192,947           4,139
Net loss (563,981)                     (355,308) (208,673)
Balance, ending balance at Dec. 31, 2010 2,991,679     48,931     11,652,516     (53) (345,000) (8,548,265) 183,550
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Purchase of subsidiary common stock             (261,174)           261,174
Sale of common stock, net of costs 3,610,993     4,717     3,606,276            
Conversion of related party convertible notes to common stock     72,959     146     72,813        
Issuance of restricted stock 253     200           53      
Issuance of subsidiary restricted stock 200                       200
Purchase of stock options (12,500)           (12,500)            
Stock based compensation expense 444,374           428,844           15,530
Net loss (1,884,794)                     (1,574,501) (310,293)
Balance, ending balance at Dec. 31, 2011 5,223,164     53,994     15,486,775       (345,000) (10,122,766) 150,161
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Sale of subsidiary common stock 500,000           289,606           210,394
Purchase of subsidiary common stock             (174,958)           174,958
Sale of common stock, net of costs 680,000     850     679,150            
Conversion of related party convertible notes to common stock   100,000 6,100   333 8   99,667 6,092        
Settlement receivable from shareholder (Note 10) 105,000     (400)     (239,600)       345,000    
Purchase of restricted stock (337)     (337)                  
Stock based compensation expense 195,545           173,253           22,292
Net loss (2,026,437)                     (1,636,957) (389,480)
Balance, ending balance at Dec. 31, 2012 4,783,035     13,725     16,360,708         (11,759,723) 168,325
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Forfeiture of restricted stock grant (350)     (150)                 (200)
Stock based compensation expense (8,105)           7,111           (15,216)
Net loss (3,616,179)                     (3,338,552) (277,627)
Balance, ending balance at Sep. 30, 2013 $ 1,158,401     $ 13,575     $ 16,367,819         $ (15,098,275) $ (124,718)